Cover Image
市場調查報告書

全球眼科用醫藥品市場 2022年:血管新生調製器及基因治療提升在預測期間內的整體收益

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

出版商 GBI Research 商品編碼 367991
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
全球眼科用醫藥品市場 2022年:血管新生調製器及基因治療提升在預測期間內的整體收益 Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period
出版日期: 2016年08月01日 內容資訊: 英文 150 Pages
簡介

全球眼科市場上收益,預計從2015年的137億美元到2022年達260億美元,以9.48%的年複合成長率成長。

本報告提供全球眼科用醫藥品市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

  • 治療領域的簡介
    • 青光眼
    • 老齡化黃斑部病變 (AMD)
    • 糖尿病黃斑部水腫
    • 糖尿病視網膜病變
    • 乾眼症症候群
  • 症狀
  • 病因、病理學
  • 合併症、併發症
  • 流行病學模式;盛行率,患者區分,及診斷、治療的使用率
    • 青光眼
    • 老齡化黃斑部病變 (AMD)
    • 糖尿病黃斑部水腫
    • 糖尿病視網膜病變
    • 乾眼症症候群
  • 治療

第3章 上市產品

  • 概要
  • Lucentis (ranibizumab)
  • Eylea (aflibercept)
  • Avastin (bevacizumab)
  • Restasis (cyclosporine)
  • Alphagan (brimonidine tartrate)
  • Lumigan (bimatoprost)
  • Xalatan (latanoprost)

第4章 開發平台形勢的評估

  • 概要
  • 開發平台開發形勢
  • 開發平台的作用機制
  • 臨床實驗
    • 失敗率
    • 臨床實驗期間
    • 臨床實驗規模
    • 臨床計劃規模的總合
    • 結論

第5章 複數方案的市場預測

  • 整體市場規模
  • 學名藥的普及
  • 收益預測:各分子標的
    • 血管新生抑制劑 (VEGF/PlGF/PDGF抑制劑)
    • 抗組織胺藥 (H1 受體)
    • 抗發炎藥 (糖皮質素受體/IL-1 受體/前列腺素受體)
    • IOP (眼內壓) 降低藥 (前列腺素/β受體阻斷劑/Rho激酶信號傳達途徑)
    • 主要開發中產品的評估

第6章 企業分析、定位

  • 收益、市場佔有率分析:各企業
  • 企業形勢
  • 上市藥、產品研發線分析

第7章 策略性討論事項

  • 授權契約
  • 共同開發契約

第8章 附錄

圖表清單

目錄
Product Code: GBIHC388MR

Executive Summary

Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues - in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.

Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.

Scope

  • Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
  • Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the ophthalmology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the ophthalmology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the ophthalmology market, globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various ophthalmology disorders.
  • Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
    • 2.1.1. Glaucoma
    • 2.1.2. Age-Related Macular Degeneration
    • 2.1.3. Diabetic Macular Edema
    • 2.1.4. Diabetic Retinopathy
    • 2.1.5. Dry Eye Syndrome
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Etiology
    • 2.3.2. Pathophysiology
  • 2.4. Co-morbidities and Complications
  • 2.5. Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
    • 2.5.1. Glaucoma
    • 2.5.2. Age-Related Macular Degeneration
    • 2.5.3. Diabetic Macular Edema
    • 2.5.4. Diabetic Retinopathy
    • 2.5.5. Dry Eye Syndrome
  • 2.6. Treatment

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Lucentis (ranibizumab)
  • 3.3. Eylea (aflibercept)
  • 3.4. Avastin (bevacizumab)
  • 3.5. Restasis (cyclosporine)
  • 3.6. Alphagan (brimonidine tartrate)
  • 3.7. Lumigan (bimatoprost)
  • 3.8. Xalatan (latanoprost)

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Mechanisms of Action in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Aggregate Clinical Program Size
    • 4.4.5. Conclusion

5. Multi-Scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors)
    • 5.3.2. Antihistamines (H1 Receptor)
    • 5.3.3. Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor)
    • 5.3.4. IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway)
    • 5.3.5. Assessment of Key Pipeline Products

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Novartis - Will Pipeline Product Approvals Offset the Patent Expiry of Lucentis?
    • 6.1.2. Bayer - Growing Revenues for Eylea Set to Increase Bayer's Revenue
    • 6.1.3. Regeneron - Growing Revenues for Eylea Will Make it the Top Selling Ophthalmology Drug
    • 6.1.4. Roche - Gradual Decline in Revenues Due to Lucentis Patent Expiries and Uptake of Generics
    • 6.1.5. Ophthotech - Pipeline Product Approval will Result in Blockbuster Status Within the Forecast Period
    • 6.1.6. Spark Therapeutics - Pipeline Product Approval to Resulting in Large Revenues in a Short Space of Time
    • 6.1.7. Santen - Patent Expiration of Eylea to Cause Gradual Decline in Revenue
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES
  • Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES
  • Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES
  • Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2016
  • Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma
  • Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2016
  • Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2016
  • Table 8: Ophthalmology Therapeutics Market, Global, Approved Indications for Avastin, 2016
  • Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2016
  • Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2016
  • Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2016
  • Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2016
  • Table 13: Ophthalmology, Global, Annual Revenue Forecast for key Products ($bn), 2015-2022
  • Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022
  • Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 16: Ophthalmology Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006-2015
  • Table 17: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016

List of Figures

  • Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2015-2022
  • Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2015-2022
  • Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2015-2022
  • Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2015-2022
  • Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2015-2022
  • Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006-2022
  • Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2006-2022
  • Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006-2022
  • Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006-2022
  • Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($m), 2006-2022
  • Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006-2022
  • Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006-2022
  • Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 15: Breakdown of Biologics in Ophthalmology Pipeline, 2016
  • Figure 16: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2016
  • Figure 17: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2016
  • Figure 18: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2016
  • Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
  • Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015
  • Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
  • Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015
  • Figure 34: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 35: Ophthalmology, Global, Market Size ($bn), 2015-2022
  • Figure 36: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Figure 37: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2015-2022
  • Figure 38: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2015-2022
  • Figure 39: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2015-2022
  • Figure 40: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2015-2022
  • Figure 41: Ophthalmology, Global, Revenue Forecast for Fovista($m), 2017-2022
  • Figure 42: Ophthalmology, Global, Revenue Forecast for SPK-RPE65 ($m), 2017-2022
  • Figure 43: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2017-2022
  • Figure 44: Ophthalmology, Global, Revenue Forecast for Rhopressa ($m), 2017-2022
  • Figure 45: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018-2022
  • Figure 46: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 47: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 48: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2014-2022
  • Figure 49: Ophthalmology, Global, Revenues by Product Type, 2014-2022
  • Figure 50: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2015-2022
  • Figure 51: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2015-2022
  • Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2015-2022
  • Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2015-2022
  • Figure 54: Ophthalmology, Global, Ophthotech Annual Revenue Forecast ($m), 2015-2022
  • Figure 55: Ophthalmology, Global, Spark Therapeutics Annual Revenue Forecast ($m), 2015-2022
  • Figure 56: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2015-2022
  • Figure 57: Ophthalmology, Global, Companies by Type, 2016
  • Figure 58: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2016
  • Figure 59: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2015-2022
  • Figure 60: Ophthalmology Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, Top Four Companies ($bn), 2015-2022
  • Figure 61: Ophthalmology, Global, Licensing Deals, 2006-2016
  • Figure 62: Ophthalmology Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 63: Ophthalmology, Global, Licensing Deals, 2006-2016
  • Figure 64: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
  • Figure 65: Ophthalmology, Global, Co-development Deals, 2006-2016
  • Figure 66: Ophthalmology, Global, Co-development Deals, 2006-2016
  • Figure 67: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016
Back to Top